Real-life data on tapering or discontinuation of canakinumab therapy in patients with familial Mediterranean fever
Author:
Publisher
Springer Science and Business Media LLC
Subject
Immunology,Immunology and Allergy,Rheumatology
Link
https://link.springer.com/content/pdf/10.1007/s00296-022-05199-w.pdf
Reference38 articles.
1. Grateau G, Duruoz MT (2010) Autoinflammatory conditions: when to suspect? How to treat? Best Pract Res Clin Rheumatol 24(3):401–411. https://doi.org/10.1016/j.berh.2009.12.009
2. Karabulut Y, Gezer HH, Duruoz MT (2022) Canakinumab is effective in patients with familial mediterranean fever resistant and intolerant to the colchicine and/or anakinra treatment. Rheumatol Int 42(1):81–86. https://doi.org/10.1007/s00296-021-04997-y
3. Ozen S (2018) Update on the epidemiology and disease outcome of familial mediterranean fever. Best Pract Res Clin Rheumatol 32(2):254–260. https://doi.org/10.1016/j.berh.2018.09.003
4. Ozen S, Bilginer Y (2014) A clinical guide to autoinflammatory diseases: familial mediterranean fever and next-of-kin. Nat Rev Rheumatol 10(3):135–147. https://doi.org/10.1038/nrrheum.2013.174
5. Ozen S, Sag E, Ben-Chetrit E, Gattorno M, Gul A, Hashkes PJ, Kone-Paut I, Lachmann HJ, Tsitsami E, Twilt M, Benedetti F, Kuemmerle-Deschner JB (2021) Defining colchicine resistance/intolerance in patients with familial Mediterranean fever: a modified-Delphi consensus approach. Rheumatology 60(8):3799–3808. https://doi.org/10.1093/rheumatology/keaa863
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Canakinumab treatment real world evidence in 3 monogenic periodic fever syndromes in 2009–2022: an interim analysis using the French JIR cohort database;Arthritis Research & Therapy;2024-04-08
2. A grey zone in canakinumab tapering: dose reduction or interval prolongation?;Rheumatology;2024-01-30
3. Is it possible to extend the dose interval of canakinumab treatment in children with familial Mediterranean fever? PeRA group experience;Pediatric Rheumatology;2023-11-23
4. A score for predicting colchicine resistance at the time of diagnosis in familial Mediterranean fever: data from the TURPAID registry;Rheumatology;2023-05-25
5. Feasibility of canakinumab withdrawal in colchicine-resistant familial Mediterranean fever;Rheumatology;2023-03-24
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3